February 13, 2026

Kura Oncology, Inc. (KURA) Stock Report: Eyeing a 304% Upside with Groundbreaking Cancer Therapies

Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company, is making waves in the biotechnology sector with its innovative approach to cancer treatment. Headquartered in San Diego, California, Kura focuses..

Praxis Precision Medicines, Inc (PRAX) Stock Analysis: A Biotech Gem with 72% Potential Upside

Praxis Precision Medicines, Inc (NASDAQ: PRAX), a burgeoning name in the biotechnology sector, is capturing the attention of investors with its significant potential upside of 72.08%. Based in Boston, Massachusetts,..

Ardelyx, Inc. (ARDX) Stock Analysis: Healthcare Innovator with Over 100% Potential Upside

Ardelyx, Inc. (NASDAQ: ARDX), a biotechnology firm specializing in addressing unmet medical needs, stands at a pivotal point in its market trajectory. The company, headquartered in Waltham, Massachusetts, is known..

Myriad Genetics, Inc. (MYGN) Stock Analysis: Navigating a 79% Potential Upside Amidst Challenging Metrics

Myriad Genetics, Inc. (NASDAQ: MYGN), a prominent player in the molecular diagnostics and precision medicine landscape, offers a diversified portfolio of genetic testing products. Despite its significant role in the..

Owens & Minor, Inc. (OMI) Stock Analysis: Is a 94.29% Upside Within Reach for Healthcare Investors?

Owens & Minor, Inc. (OMI), a stalwart in the healthcare sector specializing in medical distribution, presents a compelling case for investors seeking potential upside in a challenging market. With a..

Enhabit, Inc. (EHAB) Stock Analysis: Healthcare Growth with a 4.72% Upside Potential

Enhabit, Inc. (NASDAQ: EHAB) is steadily carving its niche in the medical care facilities sector of the healthcare industry, with a market capitalization standing at $568.75 million. Specializing in home..

Relay Therapeutics, Inc. (RLAY) Stock Analysis: 71% Upside Potential as Analysts Show Strong Buy Confidence

Relay Therapeutics, Inc. (NASDAQ: RLAY) stands out in the biotechnology sector with a significant upside potential of 71.29% according to the latest analyst ratings. This clinical-stage precision medicines company is..

EyePoint, Inc. (EYPT) Stock Analysis: A 177% Potential Upside Beckons for Investors

EyePoint, Inc. (NASDAQ: EYPT) is capturing investor attention with a staggering potential upside of 177.35%, according to analyst ratings. Operating in the dynamic biotechnology sector within the healthcare industry, EyePoint,..

RxSight, Inc. (RXST) Investor Outlook: Exploring a 33% Potential Upside in the Medical Device Sector

RxSight, Inc. (NASDAQ: RXST) is drawing attention in the healthcare sector, particularly in the medical devices industry, thanks to its innovative approach in cataract surgery solutions. Headquartered in Aliso Viejo,..

Maze Therapeutics, Inc. (MAZE) Stock Analysis: Navigating a 5.11% Potential Upside in the Biotech Space

Maze Therapeutics, Inc. (NASDAQ: MAZE) has captured the attention of investors with its promising developments in the biotechnology sector. As a clinical-stage biopharmaceutical company, Maze focuses on precision medicines targeting..

Capricor Therapeutics, Inc. (CAPR) Stock Analysis: A 114% Potential Upside in the Biotech Arena

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is capturing the attention of investors with its substantial potential upside of 114.62%, according to recent analyst ratings. As a clinical-stage biotechnology firm, Capricor is..

Trevi Therapeutics, Inc. (TRVI) Stock Analysis: A Promising 99% Potential Upside in Biotech

Trevi Therapeutics, Inc. (NASDAQ: TRVI), a pioneering clinical-stage biopharmaceutical company, has captured the attention of investors with its promising drug pipeline and significant potential upside. As the company focuses on..

Replimune Group, Inc. (REPL) Stock Analysis: Exploring a 61% Potential Upside in the Biotech Sector

Replimune Group, Inc. (NASDAQ: REPL) is garnering attention in the biotechnology industry with its innovative approach to cancer treatment. As a clinical-stage company, Replimune is focused on developing oncolytic immunotherapies,..

HealthStream, Inc. (HSTM) Stock Analysis: Exploring a 63% Potential Upside

HealthStream, Inc. (NASDAQ: HSTM), a prominent player in the healthcare information services sector, presents an intriguing opportunity for investors seeking growth in the healthcare technology space. As a Software-as-a-Service (SaaS)..

Precigen, Inc. (PGEN) Stock Analysis: Exploring a Promising 79% Upside Potential in Biotechnology

Investors with an eye on the biotechnology sector may find Precigen, Inc. (NASDAQ: PGEN) an intriguing prospect, given its focus on innovative gene and cell therapies. With a robust market..

Mind Medicine (MNMD) Stock Analysis: Exploring a 90.86% Potential Upside in the Biotech Sector

Investors with a keen interest in the biotechnology sector should take note of Mind Medicine (MindMed) Inc. (MNMD), a company positioned at the forefront of developing innovative treatments for brain..

ArriVent BioPharma, Inc. (AVBP) Stock Analysis: Exploring a Potential 79.45% Upside for Biotech Enthusiasts

ArriVent BioPharma, Inc. (NASDAQ: AVBP) has recently caught the attention of investors with its promising pipeline in the biotechnology sector. As a clinical-stage biopharmaceutical company, ArriVent is dedicated to developing..

Beta Bionics, Inc. (BBNX) Stock Analysis: Exploring the 109.72% Potential Upside and Robust Revenue Growth

Beta Bionics, Inc. (BBNX), a prominent player in the healthcare sector, is emerging as a formidable force in the medical device industry. With a current market capitalization of $596.53 million,..

SIGA Technologies Inc. (SIGA) Stock Analysis: Decoding the Investment Potential in Healthcare’s Niche Sector

SIGA Technologies Inc. (NASDAQ: SIGA) might not be a household name in the vast landscape of healthcare, but this commercial-stage pharmaceutical company is making significant strides in the health security..

Evolus, Inc. (EOLS) Stock Analysis: Healthcare Innovator with a 254% Upside Potential

Investors seeking opportunities in the healthcare sector may want to turn their attention to Evolus, Inc. (NASDAQ: EOLS), a specialty and generic drug manufacturer that has been capturing attention with..

Search

Funds

February 13, 2026

Search

Funds

February 13, 2026

FTSE 100

Funds